{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:40:10Z","timestamp":1749854410412,"version":"3.41.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","funder":[{"name":"Pfizer d.o.o.","award":["WS2319622"],"award-info":[{"award-number":["WS2319622"]}]},{"name":"Pfizer d.o.o.","award":["57121311"],"award-info":[{"award-number":["57121311"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Despite the worldwide usage of pneumococcal conjugated vaccines (PCVs), <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic> remains a major cause of morbidity and mortality among children. This study evaluated the effects of universal PCV10 vaccination on incidence, serodistribution and antimicrobial resistance among <jats:italic toggle=\"yes\">S. pneumoniae<\/jats:italic> strains causing invasive pneumococcal disease (IPD) in Croatian children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The study analyzed consecutive, nonredundant invasive <jats:italic toggle=\"yes\">S. pneumoniae<\/jats:italic> isolates obtained from children up to 18 years of age, collected through a network of microbiologic laboratories in Croatia from 2005 to 2023. Serotyping was performed by the capsular swelling method. In vitro susceptibility testing was performed according to the EUCAST guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>During the 19-year study period, 601 invasive <jats:italic toggle=\"yes\">S. pneumoniae<\/jats:italic> strains were analyzed. This included 543 isolates in the pre-PCV10 period and 58 isolates in the post-PCV10 period. Bacteremic pneumonia and serotype 3 were significantly more common in the post-PCV10 period. A significant reduction in the incidence of IPD caused by PCV10 serotypes was observed in the post-PCV10 period in all age groups, with the highest reduction of 81.0% in children &lt;5 years. The cumulative incidence of isolates susceptible, increased exposure to penicillin and isolates resistant to macrolides increased significantly slower in the post-PCV10 period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The introduction of PCV10 significantly changed the IPD epidemiology in Croatian children. The prevalence of PCV10 isolates decreased, with the current serodistribution suggesting the need for novel pneumococcal conjugates. Given the relatively low prevalence of isolates with PCV10 and PCV13 serotypes, PCV15 and PCV20 may be the most suitable candidates for future use.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004821","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T21:00:20Z","timestamp":1744750820000},"page":"708-715","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Universal PCV10 Vaccination on Invasive Pneumococcal Disease in Croatian Children"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-9192","authenticated-orcid":false,"given":"Iva","family":"Buti\u0107","sequence":"first","affiliation":[{"name":"University Hospital for Infectious Diseases, Zagreb, Croatia"},{"name":"School of Dental Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Te\u0161ovi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases, Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, Zagreb, Croatia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Boduli\u0107","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Luci\u0107","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Gro\u0161","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Gu\u017evinec","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjana","family":"Tambi\u0107 Andra\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases, Zagreb, Croatia"},{"name":"School of Dental Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of Study group for invasive isolates of Croatian Committee for Antibiotic Resistance Surveillance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"R1-20250613","first-page":"85","article-title":"Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper\u2014February 2019.","volume":"94","year":"2019","journal-title":"Wkly Epidemiol Rep"},{"year":"2024","key":"R2-20250613","article-title":"VIEW-hub report: global vaccine introduction and implementation"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"1879578","DOI":"10.1080\/21645515.2021.1879578","article-title":"Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.","volume":"18","author":"Guzman-Holst","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1473-3099(20)30489-8","article-title":"The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study.","volume":"21","author":"Agudelo","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"e0210081","DOI":"10.1371\/journal.pone.0210081","article-title":"Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.","volume":"14","author":"Richter","year":"2019","journal-title":"PLoS One"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"jiae144","DOI":"10.1093\/infdis\/jiae144","article-title":"Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries.","volume":"19","author":"Prunas","year":"2024","journal-title":"J Infect Dis"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"e0120290","DOI":"10.1371\/journal.pone.0120290","article-title":"Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children\u2014a population-based study.","volume":"10","author":"Jokinen","year":"2015","journal-title":"PLoS One"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/cid\/cix685","article-title":"Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations.","volume":"65","author":"Naucler","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"18977","DOI":"10.1038\/s41598-020-75691-5","article-title":"Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency.","volume":"10","author":"L\u00f8chen","year":"2020","journal-title":"Sci Rep"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/INF.0000000000001810","article-title":"Impact of national ten-valent pneumococcal conjugate vaccine program on reducing antimicrobial use and tympanostomy tube placements in Finland.","volume":"37","author":"Palmu","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"05001","DOI":"10.7189\/jogh.13.05001","article-title":"The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: a systematic literature review.","volume":"13","author":"Reyburn","year":"2023","journal-title":"J Glob Health"},{"key":"R13-20250613","article-title":"Implementation program of immunization, seroprophylaxis and chemoprophylaxis for special population groups and individuals at increased risk of: tuberculosis, hepatitis A and B, rabies, yellow fever, cholera, typhoid fever, tetanus, measles, severe lower respiratory tract infection caused by respiratory syncytial virus, tick-borne meningoencephalitis, chickenpox, rotavirus gastroenterocolitis, malaria, streptococcal disease (including invasive pneumococcal disease), haemophilus influenzae\u2014invasive diseases, invasive meningococcal disease, HPV infection, COVID-19 and monkeypox disease caused by monkeypox virus in 2024. [in Croatian]"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10096-011-1241-y","article-title":"Paediatric pneumococcal disease in Central Europe.","volume":"30","author":"Prymula","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R16-20250613","first-page":"101082","article-title":"The impact of pneumococcal serotype replacement on the effectiveness of a national immunization program: a population-based active surveillance cohort study in New Zealand.","volume":"46","author":"Anglemyer","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.vaccine.2020.11.018","article-title":"Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.","volume":"39","author":"Peckeu","year":"2021","journal-title":"Vaccine"},{"key":"R19-20250613","article-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net)."},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/528798","article-title":"Medical microbiology: laboratory diagnosis of invasive pneumococcal disease.","volume":"46","author":"Werno","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R21-20250613","article-title":"The European Committee on Antimicrobial Susceptibility Testing\u2014EUCAST."},{"key":"R22-20250613","first-page":"e51208","article-title":"Capsular serotyping of Streptococcus pneumoniae using the quellung reaction.","volume":"84","author":"Habib","year":"2014","journal-title":"J Vis Exp"},{"key":"R23-20250613","article-title":"Estimate of population trends (2020-2023)."},{"key":"R24-20250613","article-title":"Estimate of population trends (2007-2019)."},{"author":"Aragon","key":"R26-20250613","article-title":"Epitools: epidemiology tools\u2014R package version 0.5-10.1."},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.vaccine.2018.03.001","article-title":"Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.","volume":"36","author":"Rinta-Kokko","year":"2018","journal-title":"Vaccine"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial.","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLoS Med"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/14760584.2017.1362339","article-title":"Streptococcus pneumoniae serotype 19A: worldwide epidemiology.","volume":"16","author":"Isturiz","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"R32-20250613","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/cid\/ciy920","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies.","volume":"68","author":"Sings","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R33-20250613","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","article-title":"Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006-2018.","volume":"37","author":"Andrews","year":"2019","journal-title":"Vaccine"},{"key":"R34-20250613","doi-asserted-by":"crossref","first-page":"613287","DOI":"10.3389\/fcimb.2020.613287","article-title":"Sugar-coated killer: serotype 3 pneumococcal disease.","volume":"10","author":"Luck","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"R35-20250613","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","article-title":"Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data.","volume":"3","author":"Brueggemann","year":"2021","journal-title":"Lancet Digit Health"},{"key":"R36-20250613","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1016\/j.vaccine.2023.04.036","article-title":"A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).","volume":"41","author":"Martinon-Torres","year":"2023","journal-title":"Vaccine"},{"key":"R37-20250613","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/INF.0000000000004300","article-title":"Phase 3 safety and immunogenicity study of a three-dose series of twenty-valent pneumococcal conjugate vaccine in healthy infants and toddlers.","volume":"43","author":"Korbal","year":"2024","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:04:19Z","timestamp":1749852259000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004821","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"type":"print","value":"0891-3668"},{"type":"electronic","value":"1532-0987"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}